Y-mAbs Therapeutics, Inc. financial data

Symbol
YMAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
202 Carnegie Center, Suite 301, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 393 % -22.3%
Quick Ratio 30.6 % +7.21%
Debt-to-equity 34.1 % +24.9%
Return On Equity -31.3 % -51.1%
Return On Assets -23.4 % -43.5%
Operating Margin -35.6 % -17.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.2M shares +3.04%
Common Stock, Shares, Outstanding 45M shares +3.01%
Entity Public Float 450M USD +82.9%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 44.3M shares +1.57%
Weighted Average Number of Shares Outstanding, Diluted 44.3M shares +1.57%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 87.7M USD +3.38%
Research and Development Expense 49M USD -9.64%
Costs and Expenses 104M USD +4.8%
Operating Income (Loss) -31.2M USD -21.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29.8M USD -42.9%
Income Tax Expense (Benefit) -146K USD -126%
Net Income (Loss) Attributable to Parent -29.7M USD -38.5%
Earnings Per Share, Basic -0.67 USD/shares -36.7%
Earnings Per Share, Diluted -0.67 USD/shares -36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.2M USD -14.5%
Accounts Receivable, after Allowance for Credit Loss, Current 19.7M USD -12.3%
Inventory, Net 7.21M USD +42.4%
Other Assets, Current 4.37M USD -11.7%
Assets, Current 98.5M USD -11.3%
Property, Plant and Equipment, Net 42K USD -81.3%
Operating Lease, Right-of-Use Asset 817K USD -42.1%
Intangible Assets, Net (Excluding Goodwill) 2.28M USD -13.5%
Other Assets, Noncurrent 488K USD -10.1%
Assets 120M USD -6.23%
Accounts Payable, Current 6.66M USD +9.93%
Accrued Liabilities, Current 16.4M USD +24.6%
Liabilities, Current 23.7M USD +17.7%
Operating Lease, Liability, Noncurrent 190K USD -63.3%
Other Liabilities, Noncurrent 812K USD -6.02%
Liabilities 27.9M USD +3.78%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.26M USD +404%
Retained Earnings (Accumulated Deficit) -487M USD -6.49%
Stockholders' Equity Attributable to Parent 92M USD -8.89%
Liabilities and Equity 120M USD -6.23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.48M USD +73.5%
Net Cash Provided by (Used in) Financing Activities 588K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 45M shares +3.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.89M USD +78%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67.2M USD -14.5%
Deferred Tax Assets, Valuation Allowance 151M USD +1.5%
Operating Lease, Liability 820K USD -42.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.9M USD -24.8%
Lessee, Operating Lease, Liability, to be Paid 873K USD -42.6%
Operating Lease, Liability, Current 630K USD -30.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 187K USD -64.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 670K USD -32.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 53K USD -48.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16K USD
Deferred Tax Assets, Operating Loss Carryforwards 83.2M USD -0.01%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -146K USD
Preferred Stock, Shares Authorized 5.5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 989K USD -6.43%
Additional Paid in Capital 577M USD +3.38%
Depreciation, Depletion and Amortization 159K USD -12.6%
Share-based Payment Arrangement, Expense 14.6M USD +0.73%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%